SERUM LOW-DENSITY LIPOPROTEIN AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, AND LIVER SIZE IN SUBJECTS ON DRUGS INDUCING HEPATIC-MICROSOMAL ENZYMES
SERUM LOW-DENSITY LIPOPROTEIN AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, AND LIVER SIZE IN SUBJECTS ON DRUGS INDUCING HEPATIC-MICROSOMAL ENZYMES
复制标题
DOI：
10.1007/bf00607903
复制
发表时间：
1985-01-01
影响因子：
2.9
通讯作者：
PIRTTIAHO, HI
中科院分区：
文献类型：
--
作者：
LUOMA, PV;SOTANIEMI, EA;PIRTTIAHO, HI
在18名受试者中研究了血清低密度脂蛋白胆固醇和高密度脂蛋白胆固醇浓度及其比值、冠心病的主要危险因素和肝脏大小，这些受试者单独使用酶诱导抗惊厥药、苯妥英或与苯巴比妥和/或卡马西平联合使用。肝细胞色素P-450升高（表明肝微粒体酶诱导）的受试者显示肝脏体积增大，高密度脂蛋白浓度和高密度脂蛋白胆固醇/总胆固醇比值升高，低/高密度脂蛋白胆固醇比值降低。高密度脂蛋白胆固醇浓度及其与总胆固醇的比值与肝肿大程度成正相关，与低密度脂蛋白胆固醇与高密度脂蛋白胆固醇的比值成负相关。与肝脏大小增加相关的血清胆固醇分布特征是冠心病低风险受试者的典型特征。结果表明，酶诱导剂，如苯妥英钠和苯巴比妥，诱导肝细胞膜的结构和功能的变化与肝肿大和胆固醇分布特征的动脉粥样硬化性血管疾病的低敏感性。
Serum low-density lipoprotein cholesterol and high-density lipoprotein cholesterol concentration and the ratio between them, major risk factors of coronary heart disease, and liver size were investigated in 18 subjects who were on enzyme-inducing anticonvulsants, phenytoin alone or in combination with phenobarbital and/or carbamazepine. The subjects with a high liver cytochrome P-450, indicating hepatic microsomal enzyme induction, who showed an increase in liver size, had an elevated high-density lipoprotein concentration and high-density lipoprotein cholesterol/total cholesterol ratio, and a reduced low/high-density lipoprotein cholesterol ratio. The high-density lipoprotein cholesterol concentration and its ratio to total cholesterol were directly and related to the ratio between low and high-density lipoprotein cholesterol were inversely related to the extent of liver enlargement. The serum cholesterol distribution profile associated with an increase in liver size was typical of subjects with a low risk of coronary heart disease. The results suggest that enzyme-inducers, such as phenytoin and phenobarbital, induce structural and functional changes in hepatocellular membranes associated with liver enlargement and cholesterol distribution characteristic of low susceptibility of atherosclerotic vascular disease.